FDA rejects Capricor’s DMD cell therapy, asks for more data

Capricor Therapeutics' shares plummeted 38% in premarket trading after the FDA issued a Complete Response Letter for its Duchenne muscular dystrophy cell therapy, deramiocel, citing insufficient evidence of effectiveness and requesting more clinical data, along with chemistry, manufacturing, and controls (CMC) gaps. The company, which expects pivotal Phase 3 trial data in Q3 to address the concerns, expressed surprise given prior FDA guidance and recent leadership changes at the agency, raising questions about the FDA's current regulatory stance and potential shifts in its flexibility.

Analysis

Capricor Therapeutics (CAPR) has experienced a significant setback with the FDA's issuance of a Complete Response Letter (CRL) for its Duchenne muscular dystrophy cell therapy, deramiocel, leading to a 38% decline in its premarket share price. The rejection was based on two primary deficiencies: a lack of substantial evidence of effectiveness and unresolved issues in the chemistry, manufacturing, and controls (CMC) section of the filing. This regulatory decision introduces considerable uncertainty, particularly as the article highlights recent leadership changes within the FDA's Center for Biologics Evaluation and Research, suggesting a potential shift towards a less flexible regulatory stance. While Capricor's management expressed surprise at the CRL, the company's path forward is now critically dependent on its ongoing Phase 3 trial. The results from this 104-patient, placebo-controlled study, expected in the third quarter, are positioned as the definitive data set to address the FDA's efficacy concerns. The cancellation of a previously planned advisory committee meeting following the departure of a key FDA official further complicates the outlook, adding a layer of regulatory risk on top of the clinical and manufacturing hurdles.

Key Decisions for Investors

• Investors should recognize the heightened risk profile for Capricor following the FDA's rejection, as the path to approval for deramiocel is now extended and contingent on future data and navigating a potentially less accommodating regulatory environment.
• The primary forward-looking catalyst is the release of Phase 3 trial data in the third quarter; the outcome of this trial will be the key determinant of the asset's viability and the stock's potential for recovery.
• Given the binary nature of the upcoming clinical results and the added regulatory uncertainty, it may be prudent to await the Phase 3 data before establishing or increasing a position, as the current situation represents a high-risk bet on a single trial outcome.